Current concepts regarding calcium metabolism and bone health in sarcoidosis.
Curr Opin Pulm Med
; 23(5): 476-481, 2017 09.
Article
em En
| MEDLINE
| ID: mdl-28598871
ABSTRACT
PURPOSE OF REVIEW Vitamin D supplementation is widespread used in the general population. In sarcoidosis, up to 50% of patients, especially postmenopausal women and those taking corticosteroids, show evidence of increased bone fragility. The purpose of this review is to provide an evidence-based rationale on how to treat sarcoidosis patients with bone health issues. RECENT FINDINGS:
Evidence from observational studies show that decreased 25-hydroxy vitamin D is common in sarcoidosis. However, the great majority of sarcoidosis patents have normal or often elevated levels of 1,25-dihydroxy vitamin D (calcitriol), a marker associated with disease activity. High calcitriol levels may often be associated with hypercalcemia and hypercalcuria. The few interventional randomized controlled studies in the field, suggest that vitamin D supplementation may not be well tolerated because of hypercalcemia, moreover without substantial benefit on bone health and risk for fractures in these patients.SUMMARY:
Vitamin D supplementation may be withheld in sarcoidosis patients with bone fragility, unless calcitriol levels are below normal limits. A treating scheme is proposed.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Sarcoidose
/
Vitamina D
/
Cálcio
/
Desmineralização Patológica Óssea
/
Suplementos Nutricionais
/
Fraturas Ósseas
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Observational_studies
Limite:
Humans
Idioma:
En
Revista:
Curr Opin Pulm Med
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Grécia